• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 26th May 2011

Measuring Value with Pharmacoeconomics

In forthcoming chapter in the Oxford Handbook on the Economics of the Biopharmaceutical Industry, experts in the field outline the evolution of cost-effectiveness analysis (CEA) through its use as part of health technology assessment. The authors also explore the theoretical…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

In forthcoming chapter in the Oxford Handbook on the Economics of the Biopharmaceutical Industry, experts in the field outline the evolution of cost-effectiveness analysis (CEA) through its use as part of health technology assessment. The authors also explore the theoretical and practical issues that have arisen as the result of using CEA of drugs to make decisions about resource allocation, pricing and use and offer some important recommendations.

As both public and private payers seek to control pharmaceutical expenditures, formal cost-effectiveness analysis (CEA) has become a common approach for assessing the value of drugs, vaccines and other health technologies.  CEA usually is applied within a broader framework of health technology assessment (HTA), whereby the technology is assessed for use and/or reimbursement price considering incremental health-related effects and costs compared to existing treatments.  Australia was the first to adopt such a policy, in 1993, followed quickly by New Zealand and several provinces in Canada.  Since then, the UK has established NICE (1999) and several other European countries  request economic analyses for at least some new medicines, including Belgium, Finland, Ireland, Norway, The Netherlands, Portugal and Germany.  Similar policies have been adopted recently in some Eastern European countries, Asia and Latin America.  CEA also is used in the United States by some Medicaid programs, private insurers and health care providers, although its expansion under the 2010 health care law remains doubtful.

Adrian Towse has collaborated with outside experts in preparing a chapter that  addresses key  issues in the  forthcoming Oxford Handbook on the Economics of the Biopharmaceutical Industry. The authors outline the evolution of CEA through its use as part of HTA. They also explore the theoretical and practical issues that have arisen as the result of using CEA of drugs to make decisions about resource allocation, pricing and use.  The authors’ conclusions, in part, are that:

  • CEA has developed as part of broader HTA.  The routine use of CEA rather than cost-benefit analysis makes health care different from other areas of public policy.
  • the use of CEA for pharmaceuticals ‘if done well,’ is the most efficient form of regulation, both theoretically and in practice, but doing CEA well is the challenge.
  • incorporating a preference-base outcome measure in CEA is important.  QALYs need to be made more robust and alternatives, such as willingness to pay estimates and stated-preference discrete choice experiments, need to be explored.
  • the key parameters in CEA are the assessments of the clinical effectiveness of the health care treatment and program being evaluated, and the value of the resources they consume.  Clinical trials data usually need to be supplemented with other data and synthesized in a decision analytic model.  This remains a methodological and practical challenge.
  • harmonization of economic evaluation methods and requirements across jurisdictions face a major issue, i.e., whether estimates are transferable from one location to another.  Often this is not the case, requiring adjustments or collection of local data. Payers and manufacturers are only beginning to understand the implications of this issue.
  • in deciding the allocation of health care resources, attributes in addition to health gain may be considered – for example, the broader impact of improved health on the economy and fairness, or equity, in health care provision. A transparent approach for weighting the various attributes is essential and more structured approaches to decision making are needed, including the use of multiple-criteria decision analysis.
  • in some cases, it may be helpful to determine a “cost-effectiveness threshold” of willingness to pay, reflecting the opportunity cost of the resources consumed by treatments and programs at the margin.  Determining the level of such a threshold is not a simple task and may make sense only in health care systems with a “hard” budget constraint.
  • no matter how well CEAs are conducted, uncertainty always will exist about the estimates.  The use of “value of information” analysis can help the decision maker determine whether investment in further research might be worthwhile. One approach is to offer “coverage with evidence development” (CED) for new health technologies, granting the new medicine or device market access on condition that further research into its costs and effectiveness is completed.
  • As with all uses of scarce resources, CEA itself must deliver value for money to decision makers. CEAs need to meet decision makers’ needs without being overly complex, if this adds to cost but not to value.  Mechanisms also must exist to implement the findings of CEA, otherwise investment in CEA cannot deliver a return.

Towse, A., Drummond, M. and Sorenson, C. Measuring value: Pharmacoeconomics in theory and practice.  In Danzon, P. and Nicholson, S.  Oxford handbook on the economics of the biopharmaceutical industry. Oxford: Oxford University Press.  (forthcoming).

  • Health Technology Assessment…
  • Economics of Innovation
  • External Publications

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!